Regeneron stock gains 1.17 percent as oncology data advances

Published on 10/07/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock gained 1.17 percent on October 7, 2026, as its oncology pipeline moved toward ESMO presentations. Second-quarter revenue rose 16.7 percent.

Makroaufnahme einer transparenten Antikörper-Proteinstruktur in Blau- und Weißtönen — Regeneron Pharma US75886F1075 fokussiert eine detailreiche Makroaufnahme einer transparenten Antikörper-Proteinstruktur mit feinen Lichtreflexen, Illustration mit AI erstellt.

Regeneron Pharmaceuticals, Inc. (ISIN US75886F1075) gained 1.17 percent in Nasdaq trading on October 7, 2026, at 11:14 a.m. ET. The move followed the company's October 6 update on 10 clinical research abstracts planned for the European Society for Medical Oncology Congress.

Oncology data reaches ESMO

According to Regeneron on October 6, 2026, the company will present new findings at ESMO from October 23 to October 27, including late-breaking Phase 3 C-POST survival data for Libtayo in high-risk cutaneous squamous cell carcinoma.

The release also names a final Phase 2 analysis of neoadjuvant Libtayo and research involving Factor XI antibodies in cancer-associated thrombosis. The program spans skin, lung and ovarian cancer as well as thrombosis, giving investors several clinical milestones rather than a single product update.

Second-quarter growth sets the base

Regeneron's second-quarter revenue reached USD 4.29 billion, up 16.7 percent from the year-ago quarter, while adjusted earnings per share came to USD 14.29 versus USD 10.16 expected, according to MarketBeat. That comparison matters because the upcoming oncology data must add pipeline value to an already expanding revenue base.

The next financial checkpoint is October 30, 2026. Regeneron said it will publish third-quarter results before the U.S. market opens and hold its conference call at 8:30 a.m. ET.

Consensus target stays above USD 855

Investing.com lists a Buy consensus from 26 analysts, with an average 12-month target of USD 855.92, a high of USD 1,030 and a low of USD 730. Against the USD 747.34 Nasdaq price, the average target lies 14.53 percent above the price.

That spread leaves the October 30 results and the ESMO readouts as the next measurable tests for the valuation. The clinical presentations are investigational, so regulatory progress and trial outcomes remain more important than the number of abstracts alone.

Regeneron stock trades at USD 747.34

Regeneron stock was last at USD 747.34 on Nasdaq on October 7, 2026 at 11:14 a.m. ET. Its market capitalization was USD 77.0 billion, while the 52-week range stood at USD 541.00 to USD 859.34.